Literature DB >> 9310119

How does interferon exert its cell growth inhibitory effect?

D Grandér1, O Sangfelt, S Erickson.   

Abstract

The interferons (IFNs) have become accepted therapy in a range of haematological and non-haematological malignancies. The mechanism behind IFN's antitumour action is, however, unclear. Interferons (IFNs) are capable of modulating a variety of cellular responses. One prominent effect of IFNs is their cell growth inhibitory activity, which has also been suggested to be of major importance in their antitumour action. In the present review we will discuss the cellular events leading to a decreased number of cells following IFN treatment, the molecular mechanisms underlying these phenomena, and the importance of these effects in a clinical perspective.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9310119     DOI: 10.1111/j.1600-0609.1997.tb00965.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  9 in total

Review 1.  T-cell proliferation in vivo and the role of cytokines.

Authors:  J Sprent; X Zhang; S Sun; D Tough
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-03-29       Impact factor: 6.237

Review 2.  Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons.

Authors:  S Sun; X Zhang; D Tough; J Sprent
Journal:  Springer Semin Immunopathol       Date:  2000

3.  Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors.

Authors:  Marianne E Pavel; Ulrich Baum; Eckhart G Hahn; Johannes Hensen
Journal:  Int J Gastrointest Cancer       Date:  2005

Review 4.  Apoptosis and cell growth inhibition as antitumor effector functions of interferons.

Authors:  H Strander
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

5.  Activation of protein kinase C{eta} by type I interferons.

Authors:  Amanda J Redig; Antonella Sassano; Beata Majchrzak-Kita; Efstratios Katsoulidis; Hui Liu; Jessica K Altman; Eleanor N Fish; Amittha Wickrema; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2009-02-11       Impact factor: 5.157

6.  Update on management of midgut neuroendocrine tumors.

Authors:  Amir Mehrvarz Sarshekeh; Daniel M Halperin; Arvind Dasari
Journal:  Int J Endocr Oncol       Date:  2016-04-08

7.  Cyto-reduction of neuroendocrine tumours using Sandostatin LAR in combination with Infergen: results of a case series.

Authors:  Hank S Wang; David S Oh; Gordon V Ohning; Joseph R Pisegna
Journal:  J Pharm Pharmacol       Date:  2006-12       Impact factor: 3.765

8.  Antiproliferative Properties of Type I and Type II Interferon.

Authors:  Joseph Bekisz; Samuel Baron; Corey Balinsky; Angel Morrow; Kathryn C Zoon
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-30

9.  In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma.

Authors:  F Donskov; N Marcussen; M Hokland; R Fisker; H H T Madsen; H von der Maase
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.